Below is a list of all AbbVie clinical trials in Canada that you or someone you know might be interested in joining. Find what you’re looking for by using the filters to narrow down the results. You can also see the full list of conditions in which AbbVie deals here.
Clinical Trials
The objective of this study is to evaluate real-world effectiveness of an active drug in Canadian women with endometriosis.
A study to assess the real-life management and use of healthcare resources during the initiation of:
Canadian Real Life Evaluation of the Effect of Diet and Exercise in Prostate Cancer Patients Managed with an active drug.
This is a study for adults (18-75 years) who have successfully completed treatment either with Dupilumab or with Upadacitinib in the study M16-046.
Acute Spinal Cord Injury (SCI) is a rare injury that leads to permanent neuromotor impairment and sudden disability. Approximately 25,000 people experience cervical SCI in the United States, Europe, and Japan every year.
This study will assess the use of an active drug in adult patients with moderate to severe chronic plaque psoriasis and compare an active drug to other commonly used biologics.
This study will evaluate the safety, tolerability, and efficacy of an active drug given alone and in combination with various doses of an active drug in adults with Cystic Fibrosis who are homozygous for the F508del mutation.
This is a phase 3, randomized, multi-center study that will evaluate an active drug versus dupilumab in adults (18-75 years of age) with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.
The objective of this study is to evaluate the efficacy and safety of an active drug compared to placebo in inducing clinical remission (per Adapted Mayo score) in participants with moderately to severely active ulcerative colitis (UC).
The objective of this study is to assess the efficacy and safety of an active drug for the treatment of adolescent and adult participants with moderate to severe AD who are candidates for systemic therapy.
This protocol includes 2 standalone studies with randomization, data collection, analysis and reporting conducted independently.
The main objectives of this protocol are:
The objective of this study is to assess the efficacy and safety of an active drug combined with topical corticosteroids (TCS) for the treatment of adolescent and adult participants with moderate to severe Atopic dermatitis (AD) who are candidates for
The objective of this study is to assess the efficacy and safety of an active drug for the treatment of adolescent and adult participants with moderate to severe Atopic Dermatitis (AD) who are candidates for systemic therapy.
The main objective of this study is to evaluate safety and efficacy of an active drug in combination with azacitidine (AZA) and best supportive care (BSC) compared to BSC as maintenance therapy in adult participants with acute myeloid leukemia (AML) in
The purpose of this study is to assess the safety and efficacy of an active drug for the treatment of moderate to severe atopic dermatitis (AD) in adult and adolescent subjects.
The purpose of this study is to compare the safety and efficacy of an active drug versus placebo in subjects with moderately to severely active psoriatic arthritis (PsA).
The purpose of this study is to evaluate safety and efficacy of an active drug in subjects with ulcerative colitis (UC) in subjects who responded to induction treatment with an active drug in a prior AbbVie study of an active drug in UC.
The objectives of Sub-Study 1 are to evaluate the efficacy, safety, and pharmacokinetics of an active drug as induction treatment in subjects with moderately to severely active ulcerative colitis (UC), and to identify the appropriate induction dose of
The objective of this study is to evaluate the efficacy and safety of an active drug compared to placebo as induction therapy in participants with moderately and severely active Crohn's disease (CD).
The objective of this study is to evaluate the efficacy and safety of an active drug compared to placebo as induction therapy in subjects with moderately and severely active Crohn's disease (CD).
